Skip to main content
. 2010 Sep 21;16(35):4410–4415. doi: 10.3748/wjg.v16.i35.4410

Figure 2.

Figure 2

Serum glypican-3 levels in 32 liver cirrhosis patients and in 37 hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer-stage A and B. A: Each dot represents one patient; B: Frequencies of α-fetoprotein (AFP) ≥ 400 μg/L and glypican-3 (GPC3) > 300 ng/L in hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer-stage A and B.